Adrenomyeloneuropathy (AMN) pipeline analysis report covers more than 10 drugs currently in different phases of development. Adrenomyeloneuropathy is a genetic neurodegenerative disease caused by the mutation of ABCD1 gene. This gene makes the adrenoleukodystrophy protein (ALDP) which helps in the transport of certain types of fats in to peroxisomes. It is a form of X-linked adrenoleukodystrophy and it is also adult onset of adrenoleukodystrophy (ALD). There are two forms of AMN that vary in severity. The milder forms only affect the spinal cord while the more severe form affects both brain and spinal cord. The milder form on average, people with AMN begin to develop features in the late twenties. Signs and symptoms may include progressive stiffness and weakness of the legs, ataxia, speech difficulties, sexual dysfunction, adrenal insufficiency and bladder control issues. Some people with AMN also have brain involvement which can lead to behavioral abnormalities, vision loss, hearing problems and seizures.
The report provides Adrenomyeloneuropathy treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are medDay Pharmaceuticals, bluebird bio Inc., Minoryx Therapeutics, NeuroVia Inc., Viking Therapeutics, SOM Biotech, Receptor Pharm Inc., Applied Genetic Technologies Corporation, Biogen Inc., Vertex Pharmaceuticals Incorporated, DeueteRx, Nutra Pharma Corporation, Neural Gene, Orpheris Inc., and Apceth biopharma GmbH.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration